Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerance of Recombinant Human Albumin in Healthy Subjects
NCT04641364Phase 1Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2019
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human albumin in ascites (3 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Safety and tolerance. Started Jun 2019; status: completed.
02
Drugs
recombinant human albumin
03
Conditions
ascites
Beyond the preview
Go deeper on NCT04641364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641364.